Previous close | 39.99 |
Open | 40.16 |
Bid | 0.00 x 1800 |
Ask | 0.00 x 2900 |
Day's range | 39.99 - 40.27 |
52-week range | 39.23 - 56.32 |
Volume | |
Avg. volume | 23,245,623 |
Market cap | 225.936B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | 23.58 |
EPS (TTM) | 1.71 |
Earnings date | 02 May 2023 |
Forward dividend & yield | 1.64 (3.76%) |
Ex-dividend date | 26 Jan 2023 |
1y target est | 52.81 |
High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor. The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio.
BNTX is ranked a lowly 5 for a reason. Earnings have peaked, COVID hysteria has subsided, and the technical picture is lagging.